Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALTEROLA BIOTECH, INC.

(ABTI)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ALTEROLA BIOTECH : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

05/28/2021 | 02:39pm EDT

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words "believes," "project," "expects," "anticipates," "estimates," "intends," "strategy," "plan," "may," "will," "would," "will be," "will continue," "will likely result," and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.



Overview


The business plan of the company will no longer be focused on a chewing gum delivery system but it will re-focus its activities to the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non- cannabinoid APIs and the development of ingredients and products with the aim of achieving European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredientsfor supply into the cosmetic sector.

Because the IP relating to the development of a chewing gum with nutraceutical/functional ingredients is not relevant to the pharmaceuticaldevelopment that the company plans to undertake, the IP surrounding the chewing gum may no longer benefit the company's operations going forward. While company has not yet decided on the proper disposition of the IP at present, the company will likely divest ownership in the near future. We are in the process of updating our website to reflect this change.

The new business plan of the company is for the company's operations to be repositioned as a fully regulatory- compliant pharmaceutical company specializing in the development of the following:

• cannabinoid, cannabinoid-like and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs) globally;

   • pharmaceutical medicines made from cannabinoid, cannabinoid-like and
     non-cannabinoid APIs globally;




   • cannabinoid, cannabinoid-like and non-cannabinoid food-grade ingredients with
     the aim of achieving European novel food approval of such ingredients;

• non-pharmaceutical (nutraceutical / dietary supplement) productscontaining cannabinoids, cannabinoid-like and non-cannabinoid food-grade ingredients with the aim of achieving European novel food approval of such products; and

• Supply of cosmetic ingredients to potential customers who may develop products containing cannabinoids, cannabinoid-like and non-cannabinoid ingredients

The controlled drugs / cannabinoid pharmaceutical market worldwide has experienced exponential growth over the past few years in the development of cannabinoid medicines. It is Alterola's intention to develop ingredients and products on a global basis, fully compliant with the appropriate international laws and regulations and also compliant with the relevant national laws and regulations on a territory-by-territory basis.



  4


  Table of Contents



In December 2020, the company retained new management and board members that have experience in the pharmaceutical, botanical and nutraceutical industries. Further to this objective, the company is also interested in recruiting key executives and personnel that have experience in the controlled drugs / cannabinoid medicines industry. The focus will be on recruiting outstanding talents that have contributed or can contribute more in the future with the company's expansion plans.

The company also has interest in licensing / acquiring other IP from companies that have IP pertinent to the aforementioned products the company plans to develop. Under consideration are companies that have existing pharmaceutical research and/or development or manufacturing capability or associated IP. Some of these companies have IP which is available to integrate into our company strategy. These acquisition or in-licensing opportunities are expected to facilitate the company to develop API and medicines globally and food-grade ingredients and products for the food and beverage industry in Europe.



Acquisition of ABTI Pharma


On January 19, 2021, we entered into an Stock Transfer Agreement (the "Agreement") with ABTI Pharma Limited, a company registered in England and Wales ("ABTI Pharma"), pursuant to which the Company will acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 shares of the Company pro rata to the ABTI Pharma shareholders.

On May 24, 2021, we and the shareholders of ABTI Pharma memorialized a new closing date in an amendment to the Agreement (the "Amendment"). We have already issued the 600,000,000 shares in anticipation of the closing and the transaction closed on May 26, 2021, upon the filing of our December 31, 2020 quarterly report on Form 10-Q with the Securities and Exchange Commission.

Pursuant to the Agreement, from the date of execution, the Company will provide funding to ABTI Pharma to pay for operating expenses including salaries, office expenses and additional expenses or projects in the amount of US$500,000 within fifteen (15) days from closing the Agreement and shall fund an additional US $200,000 every 30 days thereafter until a total funding of US $1,100,000 has been delivered.

Further under the Agreement, Alterola will endeavor to raise a total of at least $50,000,000 with $45,000,000 in net proceeds and Alterola will arrange an underwriting commitment of the first ($25,000,000 USD) to be funded at a price of not less than $1.00 per share within 45 days of execution of the Agreement .

As part of the Agreement, Amsterdam Café Holdings Limited cancelled and returned to us 200,000,000 shares it holds and we issued Bulls Run Investments Limited 19,100,000 shares of common stock.

Results of Operations for the Three Months Ended December 31, 2020 and 2019

We have generated no revenues since inception and we do not anticipate earning revenues until such time that we are able to market and sell our products.

We incurred operating expenses of $62,000 for the three months ended December 31, 2020, compared with $104,693 for the three months ended December 31, 2019.

Our operating expenses for the three months ended December 31, 2020 mainly consisted of $30,000 in director fees, and $32,000 in stock based compensation. Our operating expenses for the three months ended December 31, 2019 mainly consisted of $60,000 in consulting fees, $30,000 in director fees and $10,250 in accounting and audit fees.

We recorded other expense of $0 for the three months ended December 31, 2020, as compared with other income of $79,000 in interest expense for the three months ended December 31, 2019. Our other income for December 31, 2019 consisted of third party consideration to the company for effecting a change in stock symbol.

We recorded a net loss of $62,000 for the three months ended December 31, 2020, compared with a net loss of $25,693 for the three months ended December 31, 2019.



  5


  Table of Contents



Liquidity and Capital Resources

As of December 31, 2020, we had $15,273 in current assets and currently liabilities of $368,494. We had a working capital deficit of $353,221 as of December 31, 2020, as compared with a working capital deficit of $323,221 as of September 30, 2020.

We had no operating, investing or financing cash flows to report for the three months ended December 31, 2020 and 2019.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next 12 months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.

Off Balance Sheet Arrangements

As of December 31, 2020, we had no off balance sheet arrangements.



Going Concern


Our financial statements were prepared assuming we will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred cumulative losses of $1,283,788 for the period July 21, 2008 (inception date) through December 31, 2020, expect to incur further losses in the development of our business and have been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about our ability to continue as a going concern. Management's plans include continuing to finance operations through the private or public placement of debt and/or equity securities and the reduction of expenditures. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

© Edgar Online, source Glimpses

All news about ALTEROLA BIOTECH, INC.
10/05ALTEROLA BIOTECH : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Inter..
MT
10/05ALTEROLA BIOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/05Alterola Biotech, Inc. Announces Executive Changes
CI
10/05Alterola Biotech, Inc. Announces Executive Changes
CI
09/23Alterola Biotech, Inc. Confirms Appointment of Hunter Land to the Board
CI
08/19ALTEROLA BIOTECH : Management's Discussion and Analysis of Financial Condition and Results..
AQ
08/02ALTEROLA BIOTECH : acquires ABTI pharma ltd
AQ
06/21ALTEROLA BIOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/16ALTEROLA BIOTECH INC. : Entry into a Material Definitive Agreement, Completion of Acquisit..
AQ
06/16ABTI Pharma Limited completed the acquisition of Alterola Biotech, Inc. in reverse merg..
CI
More news
Chart ALTEROLA BIOTECH, INC.
Duration : Period :
Alterola Biotech, Inc. Technical Analysis Chart | ABTI | US02152V1035 | MarketScreener
Managers and Directors
Seamus McAuley Chief Executive Officer & Secretary
Timothy Paul Rogers Chairman & Chief Financial Officer
Colin Stott Chief Operating Officer & Director
Dominic Schiller Director
Daniel S. Reshef Director
Sector and Competitors
1st jan.Capi. (M$)
ALTEROLA BIOTECH, INC.6.84%261
GILEAD SCIENCES, INC.14.83%83 880
WUXI APPTEC CO., LTD.29.16%66 875
BIONTECH SE222.44%63 484
REGENERON PHARMACEUTICALS14.28%57 402
VERTEX PHARMACEUTICALS-21.55%48 101